Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15136697.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide. The authors report three patients with EA2 (two with proven mutations in the CACNA1A gene) whose attacks were prevented with the potassium channel blocker 4-aminopyridine (4-AP; 5 mg tid). Attacks recurred after treatment was stopped; subsequent treatment alleviated the symptoms (mean follow-up time 6 months). These effects might be due to an improvement of the impaired functioning of Purkinje cells.
Medical subject headings
- 4-Aminopyridine
- Ataxia
- Potassium Channel Blockers